Results 171 to 180 of about 145,099 (296)

Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants

British Journal of Haematology, EarlyView.
Summary Constitutional pathogenic variants in DDX41 predispose to myelodysplasia and acute myeloid leukaemia. Acquisition of subsequent somatic hits in the second allele is frequent, with notable recurrent variants at key hotspots. Sequencing of Deoxyribonucleic acid from blood/marrow of 239 patients with suspected/confirmed haematological malignancies
Andrew George, Elisabeth Rolf, Monika Domeradzka, Sara Ribeiro, Brittany Mills, April Hallett, Suzanne Macmahon, Paula Proszek, Ridwan Shaikh, Lina Yuan, Michael Hubank, Mikel Valganon Petrizan, Terri P. McVeigh, Jamshid S. Khorashad   +13 more
wiley   +1 more source

Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab

British Journal of Haematology, EarlyView.
Summary Front‐Line therapy in CLL: Assessment of Ibrutinib‐containing Regimens (FLAIR) demonstrated improved progression‐free survival for ibrutinib and rituximab (IR) compared with fludarabine, cyclophosphamide and rituximab (FCR) in previously untreated chronic lymphocytic leukaemia (CLL).
David J. Allsup, David A. Cairns, E. Faye Samy, Lelia Duley, Adrian Bloor, Abraham Varghese, David Meads, Bryony Dawkins, Sean Girvan, Dena R. Howard, Anna Hockaday, Julia M. Brown, Sharon Jackson, Natasha Greatorex, Phoebe Templeton, Michael Tupper, David Phillips, Sonam Yaqub, Di Mortimer, David Stones, Piers E. M. Patten, Andrew Rawstron, Peter Hillmen, Talha Munir   +23 more
wiley   +1 more source

Contraceptives in chronic lymphocytic leukemia (CLL): a narrative review. [PDF]

Ann Hematol
Al-Shibly R, Qassim N, Alfarsi K, AlShemmari S, Yassin M.   +4 more
europepmc   +1 more source

Chemotherapy‐driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Chemotherapy‐induced WNT ligand secretion by bone marrow (BM) stroma drives acute lymphoblastic leukaemia (ALL) chemoresistance. WNT pathway inhibition disrupts this cross‐talk and restores therapeutic response, highlighting WNT inhibitors as a promising strategy to prevent relapse in ALL.
Foteini Kalampalika, Amanda Jiménez‐Pompa, Raúl Sánchez‐Lanzas, Bela Patel, Miguel Ganuza   +4 more
wiley   +1 more source

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study. [PDF]

Cancer
Coste A, Sritharan N, Lok A, Tomowiak C, Ferrant E, Clavert A, Roos-Weil D, Bouclet F, Caillet A, Croizier C, Stocker N, Tchernonog E, Feugier P, Santagostino A, Hivert B, Michallet AS, De Guibert S, Lara D, Waultier-Rascalou A, Merabet F, Durand A, Bussot L, Laribi K, Dilhuydy MS, Lévy V, Quinquenel A.   +25 more
europepmc   +1 more source

Interferon-alpha 2b early phase chronic Lymphocytic Leukemia with high risk for progression-first results of a randomized multicenter AIO-Study [PDF]

, 1992
Dietzfelbinger, H., Emmerich, B., Knauf, W. U., Langenmayer, Irmgard, Mausbach, P., Nerl, C., Thiel, E., Ziegler-Heitbrock, H. W.   +7 more
core   +1 more source

Circulating levels of insulin‐like growth factor I (IGF‐I) and risk of multiple myeloma: An observational and Mendelian randomisation study

British Journal of Haematology, EarlyView.
Summary Evidence for an association between insulin‐like growth factors (IGF) and multiple myeloma (MM) is inconsistent. We examined total IGF‐I concentrations and risk of MM by combining baseline serological data among UK Biobank participants (n = 444 187; 732 incident MM) with a two‐sample Mendelian randomisation (MR) analysis using identified ...
Yolanda Benavente, Sara Hermosa, Nikos Papadimitriou, Alyssa Clay‐Gilmour, Elizabeth E. Brown, Jonathan N. Hofmann, Nathaniel Rothman, Qing Lan, Sonja I. Berndt, Demetrius Albanes, Mark Purdue, Mitchell J. Machiela, Stephen J. Chanock, Parveen Bhatti, Wendy Cozen, Aaron Norman, Susan L. Slager, James R. Cerhan, Vincent Rajkumar, Shaji K. Kumar, Celine M. Vachon, Anne J. Novak, Thomas M. Habermann, Brian K. Link, Gilles Salles, Herve Ghesquieres, Paige M. Bracci, Elizabeth Holly, Rosalie G. Griffin, Michelle A. T. Hildebrandt, Roel C. H. Vermeulen, P. Martijn Kolijn, Henrik Hjalgrim, Karin Ekström Smedby, Harindra Jayasekara, Simon Cheah, Alain Monnereau, Yu Chen, Alan Arslan, Yawei Zhang, Nicola J. Camp, Douglas W. Sborov, Afaf E. G. Osman, Elad Ziv, Immaculata De Vivo, Vijai Joseph, Lauren R. Teras, Alpa V. Patel, Eleanor Kane, Claire M. Vajdic, Adrien Guilloteau, Pierluigi Cocco, Laia Alemany, Juan Sainz, James McKay, Brenda M. Birmann, Delphine Casabonne   +56 more
wiley   +1 more source

Mitochondrial heteroplasmy is a risk factor for the development of chronic lymphocytic leukemia. [PDF]

Nat Commun
Pasca S, Hong YS, Shi W, Puiu D, Lake NJ, Lek M, Guallar E, Arking DE, Gondek LP.   +8 more
europepmc   +1 more source

Treosulfan–fludarabine conditioning in infants with severe combined immunodeficiencies: Extended study of the UK paediatric treosulfan study

British Journal of Haematology, EarlyView.
Summary Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for severe combined immunodeficiency (SCID). Conditioning improves donor engraftment and freedom from immunoglobulin replacement (IgR) but increases the risks of acute and late toxicity. Treosulfan, a reduced toxicity alkylating agent, has emerged as an alternative
Su Han Lum, Sinéad Greener, Irum Latif Memon, Persis Amrolia, Zohreh Nademi, Robert Chiesa, Juliana Silva, Helen Young, Stephen Owens, Eleri Williams, Khuen Foong Ng, Terry Flood, Andrew R Gennery, Sophie Hambleton, Kanchan Rao, Mary Slatter   +15 more
wiley   +1 more source

Rod-Like Cytoplasmic Inclusions in the Peripheral Blood Smear of a Patient with Chronic Lymphocytic Leukemia. [PDF]

EJHaem
Prasad A, Nguyen TB, Carrillo LF.
europepmc   +1 more source